|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
G-protein coupled glucagon receptors (GCGRs) play an important role in glucose homeostasis and pathophysiology of Type-II Diabetes Mellitus (T2DM).
|
31443129 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dual GLP-1R/GCGR Agonist SAR425899 Improves Beta-cell Function in Type 2 Diabetes.
|
31808298 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
To evaluate the safety, pharmacokinetics and pharmacodynamics of SAR425899, a novel polypeptide, active as an agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCR), in healthy volunteers and in overweight/obese patients with type 2 diabetes (T2D).
|
30091218 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Antisense Inhibition of Glucagon Receptor by IONIS-GCGR<sub>Rx</sub> Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.
|
30765435 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Antagonists of the glucagon receptor have been considered as glucose-lowering therapy in type 2 diabetes patients, but their clinical applicability has been questioned because of reports of therapy-induced increments in liver fat content and increased plasma concentrations of low-density lipoprotein.
|
31068828 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
|
31786794 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
These potent GCGR antagonists could be used for potential treatment of type II diabetes.
|
31138472 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The glucagon receptor is a central target in novel and anticipated type 2 diabetes therapies, and hemodynamic consequences of glucagon signaling have therefore become increasingly important.
|
29546411 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the efficacy, tolerability, and safety of treatment with MEDI0382, a balanced glucagon-like peptide-1 and glucagon receptor dual agonist developed to provide glycaemic control and weight loss, in patients with type 2 diabetes.
|
29945727 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To conduct a dose-response assessment of the efficacy and safety of the glucagon receptor antagonist PF-06291874 in adults with type 2 diabetes (T2DM) using stable doses of metformin.
|
29923286 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
|
30203123 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
To investigate the metabolic effects of glucagon receptor antagonism in type 2 diabetes, we treated Lepr<sup>db/db</sup> and Lep<sup>ob/ob</sup> mice with REMD 2.59, a human monoclonal antibody and competitive antagonist of the glucagon receptor.
|
29444429 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Glucagon receptor (GCGR) blockers are being investigated as potential therapeutics for type 1 and type 2 diabetes.
|
28755409 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, the inhibition of glucagon receptor is one target for the treatment of hyperglycemia in type 2 diabetes.
|
30366787 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The present observations provide experimental evidence that hyperglucagonemia in type 2 diabetes promotes colon cancer progression via GCGR-mediated regulation of AMPK and MAPK pathways.
|
29535833 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
MEDI0382 is a balanced glucagon-like peptide-1/glucagon receptor dual agonist under development for the treatment of type 2 diabetes mellitus and non-alcoholic steatohepatitis.
|
29926478 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy.
|
30391422 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The implications of these findings are very important for the management of type 2 diabetes given that GLP-1 receptor agonist are currently approved for the treatment of hyperglycemia and glucagon receptor antagonists and GLP-1/glucagon dual agonists are under development.
|
28463898 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus.
|
27501510 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The human glucagon receptor, GCGR, belongs to the class B G-protein-coupled receptor family and plays a key role in glucose homeostasis and the pathophysiology of type 2 diabetes.
|
28514451 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
|
28191913 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Pharmacotherapy of T2D is becoming a highly competitive field so that GCGr antagonists should provide clear advantages over numerous existing glucose-lowering medications before eventually reaching clinical practice.
|
29052441 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
|
28237861 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Soy protein increases GR recycling to the membrane of adipocytes and its ligand-binding and G protein selectivity, suggesting, it could be used in T2D dietary treatment to reestablish glucagon sensitivity in WAT, leading to the regulation of circulating glucagon levels.
|
28654184 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, it remains obscure of the exact characteristics of hepatic Gsα-cAMP signal axis (including Gsα, glucagon receptor, β<sub>2</sub>-adrenergic receptor, cAMP, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase) in insulin resistance (IR) and type 2 diabetes mellitus (T2DM).
|
28260721 |
2017 |